CRESTONE, INC.
CRS3123, a narrow-spectrum antibacterial molecule that selectively inhibits bacterial methionyl-tRNA synthetase to target pathogenic Enterococcus species in the gut
- Sector
- Biotech
- Total capital
- $63.4M
- Federal grants
- $1.9M
- 4 awards · 2015–2023
- Rank in peer group#64 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $61.5M
- 5 awards · Health and Human S, Veterans Affairs
- Rank in Biotech#13 of 4373
- Granted patents
- 1
- 14 pending · first 2023
- Rank in peer group#80 of 326
Capital timeline
Latest events
- Federal contractVeterans Affairs · Synthesis And Testing Laboratory Services For Research$99K
- Federal contractVeterans Affairs · Synthesis And Testing Of Novel Antibiotic Chemical Compounds For Rocky Mountain Regional Va Medical Center Research Department$102K
- Federal grantHealth and Human S · Phase I · A Novel Small Molecule Therapeutic for Acute Graft Versus Host Disease$296K
- Federal contractHealth and Human S · To Advance A Promising, Small-molecule Compound CRS0540 To Ind Filing And Through Phase I Clinical Studies.$22M
- Federal grantHealth and Human S · Phase I · Preclinical Evaluation of CRS3123 for the Treatment of Helicobacter pylori Infections$144K
- Federal contractHealth and Human S · To Make An Award Under HHS-NIH-NIAID-BAA2018$33.3M
- Federal grantHealth and Human S · Phase II · Optimization and Lead Selection of Novel Antimycobacterial Agents$716K
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase II · Optimization and Lead Selection of Novel Antimycobacterial Agents$761K
- Federal contractHealth and Human S · Igf::ot::igf - Optimization Of Polc Polymerase Inhibitors For Treatment Of High Priority Gram-positive Pathogens.$5.9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#64 · top 20%
- Granted patents#80 · top 25%
- Linked publications#18 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 15- PendingBacterial Efflux Pump Inhibitors And Methods Of UseUSPTOApplication 18294248
- PendingMethods And Compounds For Treatment Of Autism Spectrum DisorderUSPTOApplication 18038401
- GrantedNovel Antimycobacterial Heterocyclic AmidesUSPTOUS 11,655,225
Show all 15 patent records
- Bacterial Efflux Pump Inhibitors And Methods Of UseOct 24, 2024 · Application 18294248Pending
- Methods And Compounds For Treatment Of Autism Spectrum DisorderJan 4, 2024 · Application 18038401Pending
- Novel Antimycobacterial Heterocyclic AmidesMay 23, 2023 · US 11,655,225Granted
- Bacterial Efflux Pump Inhibitors And Methods Of UseApplication PCTUS2022031944Pending
- Novel 6-AZAURIDINE Compounds As Broad Spectrum Antiviral AgentsApplication 63331461Pending
- Methods And Compounds For Treatment Of Autism Spectrum DisorderApplication PCTUS2021062454Pending
- Bacterial Efflux Pump Inhibitors And Methods Of UseApplication 63228541Pending
- Methods And Compounds for Treatment of Autism Spectrum DisorderApplication 63123453Pending
- Novel Antimycobacterial Heterocyclic AmidesApplication PCTUS2019020095Pending
- Novel Antimycobacterial Heterocyclic AmidesApplication 62636328Pending
- Enantiomeric Compounds With Antibacterial ActivityApplication PCTUS2007078144Pending
- Intermediates, Formulations, Syntheses, Polymorphs, And Salt Forms Of CRS3123Application PCTUS2025045309Pending
- Substituted Thienopyridone Compounds With Antibacterial ActivityApplication PCTUS2007078124Pending
- Formulations, Syntheses, Polymorphs, And Salt Forms Of CRS3123Application 63691870Pending
- Novel 6-AZAURIDINE Compounds As Broad Spectrum Antiviral AgentsApplication PCTUS2023018706Pending
Recent research by its founders
- Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study20263 cites
- Friction Modulation via Ring-Size Engineering of Polyrotaxanes for Synergistically Tough and Low-Hysteresis Ionogels20261 cites
- Acid-Free Synthesis of MIL-101/GO Composites with Ultrahigh Selectivity for Adsorptive Separation of C3F8 from N220260 cites
Related companies, and why
- CONTINUUS Pharmaceuticals, Inc.Similar federal contract value in Biotech · $73.7M in contracts
- GUILD ASSOCIATES INCSimilar federal contract value in Biotech · $69.6M in contracts
- Spero Therapeutics, Inc.Similar federal contract value in Biotech · $65.6M in contracts
- Cidara TherapeuticsSimilar federal contract value in Biotech · $58.1M in contracts
- 3D SystemsSimilar federal contract value in Biotech · $52.7M in contracts
- Cempra PharmaceuticalsSimilar federal contract value in Biotech · $52.5M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .